- - | |
---|---|
Price | |
- | |
Difference | - (-) |
ISIN | CH1276028821 |
Symbol | SANN |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 119 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | - |
High | - |
Low | - |
Close (prev. day) | - |
VWAP | - |
Volume (pcs) | - |
Trading volume | - |
Number of trades | - |
Last size | - |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/10/08 | Global Strategy 4Q 2024 | ||
2024/09/27 | Global Equity Ratings | ||
2024/09/11 | Global Equity Ratings | ||
2024/08/12 | Global Equity Ratings | ||
2024/07/12 | Global Equity Ratings |
- - | |
---|---|
Price | |
- | |
Difference | - (-) |
ISIN | CH1276028821 |
Symbol | SANN |
Exchange | Stuttgart |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 119 EUR |
Benchmark | SWISS MARKET INDEX |
Bid (Bid size) | - |
Ask (Ask size) | - |
Open | - |
High | - |
Low | - |
Close (prev. day) | - |
VWAP | - |
Volume (pcs) | - |
Trading volume | - |
Number of trades | - |
Last size | - |
6m | 1Y | 3Y | |
Perf (%) | - | - | - |
Perf (abs.) | - | - | - |
Beta | 0.35 | 0.55 | -0.15 |
Volatility | - | - | - |
Ø price 5 days | Ø volume 5 days (pcs.) | - EUR (-) |
Ø price 30 days | Ø volume 30 days (pcs.) | - EUR (-) |
Ø price 100 days | Ø volume 100 days (pcs.) | - EUR (-) |
Ø price 250 days | Ø volume 250 days (pcs.) | - EUR (-) |
YTD High | date | - EUR (-) |
YTD Low | date | - EUR (-) |
52 Weeks High | date | - EUR (-) |
52 Weeks Low | date | - EUR (-) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | - | - | - | 0.00 | - |
SIX Swiss Exchange | 2024/10/18 | 17:30 | 9.19 CHF | 0.03 | 35 |
London Stock Exchange | 2021/06/11 | 13:10 | 29.1736 CHF | 0.00 | 1 |
Frankfurt | 2019/06/28 | 08:04 | 136.40 EUR | 0.00 | 2 |
FINRA other OTC Issues | 2024/02/22 | 18:23 | 11.70 USD | 0.01 | 2 |
Berlin | 2019/06/28 | 15:59 | 137.20 EUR | 0.00 | 5 |
SANTHERA PHARMACEUTICALS HOLDING AG |
- - |
Hohenrainstrasse 24 - 4133 Pratteln |
Telefon: +41-61-906-89-50 |
Fax: +41-61-906-89-51 |
E-mail: office@santhera.com |
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. Its product pipeline includes Vamorolone and Lonodelestat. The company was founded by Thomas Meier in 1998 and is headquartered in Pratteln, Switzerland. |
Dario Eklund | Chairman of Managing Board |
Ana Vera | Member of Executive Committee |
Andrew Smith | Member of Executive Committee |
Geert Jan van Daal | Member of Executive Committee |
Günther Metz | Member of Executive Committee |
Neville Kodkani | Member of Executive Committee |
Oliver Kronenberg | Member of Executive Committee |
Andreas Missy | Member of Executive Committee |
Marc Schrader | Member of Executive Committee |
Oliver Strub | Member of Executive Committee |
Sabine Pilot | Member of Executive Committee |
Sarah Holmes-Klotz | Member of Executive Committee |
Otto Schwarz | Member of the administrative board |
Shabir Hasham | Member of the administrative board |
Bradley Meyer | Member of the administrative board |
Philipp Gutzwiller | Member of the administrative board |
Thomas Meier | Chairman of the administrative boar |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer